
Affimed N.V. AFMD
Quarterly report 2022-Q2
added 08-11-2022
Affimed N.V. Book Value 2011-2026 | AFMD
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value Affimed N.V.
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| - | 72 M | 38.7 M | 40.1 M | 31.6 M | 38.8 M | 67.3 M | 31.8 M | -99.2 M | -73.1 M | - |
All numbers in EUR currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 72 M | -99.2 M | 16.4 M |
Quarterly Book Value Affimed N.V.
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 261 M | - | 225 M | - | 248 M | - | 176 M | - | 101 M | - | 112 M | - | 99.1 M | - | 116 M | - | - | - | 43.2 M | - | - | - | 48.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in EUR currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 261 M | 43.2 M | 143 M |
Book Value of other stocks in the Biotechnology industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
49 M | - | 2.43 % | $ 254 M | ||
|
Acer Therapeutics
ACER
|
-16.8 M | - | 2.71 % | $ 14 M | ||
|
Acorda Therapeutics
ACOR
|
109 M | - | -24.86 % | $ 820 K | ||
|
ADMA Biologics
ADMA
|
477 M | $ 16.49 | -0.3 % | $ 3.93 B | ||
|
AgeX Therapeutics
AGE
|
5.36 M | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
715 M | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
29.5 M | - | - | $ 26.5 M | ||
|
AbCellera Biologics
ABCL
|
967 M | $ 3.59 | -1.1 % | $ 1.07 B | ||
|
I-Mab
IMAB
|
5.63 B | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
253 M | - | - | $ 40.3 B | ||
|
Biophytis SA
BPTS
|
34.9 M | - | -13.47 % | $ 169 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.33 B | - | -1.52 % | $ 24.7 M | ||
|
Midatech Pharma plc
MTP
|
8.32 M | - | -18.52 % | $ 27.3 M | ||
|
Akero Therapeutics
AKRO
|
750 M | - | - | $ 3.67 B | ||
|
Akouos
AKUS
|
234 M | - | 0.23 % | $ 488 M | ||
|
Alpine Immune Sciences
ALPN
|
179 M | - | - | $ 2.17 B | ||
|
AlloVir
ALVR
|
113 M | - | 4.14 % | $ 49.1 M | ||
|
Apellis Pharmaceuticals
APLS
|
370 M | $ 20.5 | 3.22 % | $ 2.59 B | ||
|
Aptorum Group Limited
APM
|
11.8 M | $ 0.81 | -1.57 % | $ 4.42 M | ||
|
Ampio Pharmaceuticals
AMPE
|
3.36 M | - | -11.43 % | $ 502 K | ||
|
ANI Pharmaceuticals
ANIP
|
429 M | $ 75.14 | -1.82 % | $ 1.45 B | ||
|
Applied Therapeutics
APLT
|
-17.1 M | - | - | $ 8.42 M | ||
|
Aravive
ARAV
|
10.7 M | - | -13.39 % | $ 1.45 M | ||
|
Autolus Therapeutics plc
AUTL
|
427 M | $ 1.57 | -3.68 % | $ 401 M | ||
|
Adverum Biotechnologies
ADVM
|
70.7 M | - | - | $ 86.2 M | ||
|
Институт стволовых клеток человека
ISKJ
|
10.6 M | - | - | - | ||
|
Athersys
ATHX
|
60.2 M | - | 3.77 % | $ 22.4 M | ||
|
ARCA biopharma
ABIO
|
382 M | - | 1052.0 % | $ 415 M | ||
|
AVEO Pharmaceuticals
AVEO
|
45.9 M | - | - | $ 521 M | ||
|
Axsome Therapeutics
AXSM
|
88.3 M | $ 163.09 | -0.61 % | $ 8.11 B | ||
|
Champions Oncology
CSBR
|
3.77 M | $ 6.0 | - | $ 82 M | ||
|
BridgeBio Pharma
BBIO
|
-2.08 B | $ 65.5 | -1.57 % | $ 12.5 B | ||
|
Brainstorm Cell Therapeutics
BCLI
|
-7.76 M | - | -2.5 % | $ 5.88 M | ||
|
BioDelivery Sciences International
BDSI
|
188 M | - | -4.8 % | $ 255 M | ||
|
Acasti Pharma
ACST
|
66.6 M | - | 4.01 % | $ 150 M | ||
|
BeiGene, Ltd.
BGNE
|
4.36 B | - | 0.49 % | $ 251 B | ||
|
Bellicum Pharmaceuticals
BLCM
|
20.1 M | - | -9.72 % | $ 5.89 M | ||
|
Berkeley Lights
BLI
|
142 M | - | -7.31 % | $ 87 M | ||
|
CureVac N.V.
CVAC
|
688 M | - | - | $ 867 M | ||
|
Aeterna Zentaris
AEZS
|
13.2 M | - | 5.93 % | $ 314 M | ||
|
Bellerophon Therapeutics
BLPH
|
2.53 M | - | -74.18 % | $ 955 K | ||
|
BioLineRx Ltd.
BLRX
|
13.5 M | $ 2.84 | 1.07 % | $ 908 M | ||
|
BioMarin Pharmaceutical
BMRN
|
6.09 B | $ 60.3 | -0.22 % | $ 11.6 B | ||
|
Burford Capital Limited
BUR
|
1.66 B | $ 8.34 | -0.48 % | $ 1.36 B | ||
|
Cabaletta Bio
CABA
|
236 M | $ 3.37 | -1.75 % | $ 3.94 M | ||
|
AIkido Pharma
AIKI
|
39.9 M | - | 1.93 % | $ 17.4 M | ||
|
Agenus
AGEN
|
314 M | $ 3.04 | -5.0 % | $ 1.09 M | ||
|
Galmed Pharmaceuticals Ltd.
GLMD
|
36.6 M | $ 0.59 | - | $ 549 K | ||
|
Ayala Pharmaceuticals
AYLA
|
7.77 M | - | - | $ 7.46 M | ||
|
Capricor Therapeutics
CAPR
|
22.6 M | $ 25.56 | 0.22 % | $ 684 M |